Vericel Corporation (VCEL)

Vericel's stock has been impacted by several events in the past six months. In January 2026, the stock decreased by 7.0% after issuing preliminary guidance for Q4 and full year 2025, reporting $276 million in total net revenue. In December 2025, Truist Securities reduced its price target on Vericel to $45 from $50. In November 2025, Vericel reported Q3 2025 financial results with an EPS of $0.10, beating estimates by $0.12, and revenue up 16.6% year-over-year. In July 2025, Vericel announced Q2 2025 financial results, with MACI revenue increasing by 21% year-over-year. Overall, VCEL's stock price has seen a slight decrease of 0.64% over the past six months.

Analysis of Vericel Corp. seasonal charts suggests a potential seasonal pattern for its stock performance, with a "Buy Date of October 16 and a Sell Date of January 10" showing positive returns above the S&P 500 Total Return Index over the past 20 years. MACI, Epicel, and NexoBrid are considered needs-based products, which are recession-resistant. Vericel also focuses on enhancing manufacturing processes for its cell therapy products to improve efficiency and meet increasing demand.

Vericel Corp. is a biopharmaceutical company focused on developing, manufacturing, and commercializing advanced cell therapy products for sports medicine and severe burn care. Its key products include MACI, an autologous cellularized scaffold for knee cartilage repair, Epicel, a permanent skin replacement for burn patients, and NexoBrid, a biological product for eschar removal in burn patients. MACI Arthro was launched in Q3 2024 to improve physician usability and patient recovery, and a Phase III study for MACI Ankle is planned for the latter half of 2025. NexoBrid received FDA approval in December 2022 and its indication was expanded to include pediatric patients in August 2024.

Vericel Corp.'s commercial activities and revenue generation are primarily concentrated within the United States, where its key products are marketed and distributed. The company's business strategy is centered on the U.S. market, where all its revenue is generated. Vericel operates manufacturing facilities and is headquartered in Cambridge, Massachusetts. While currently focused on the U.S., Vericel plans to enter international markets between 2027 and 2028 and collaborates with partners for commercialization outside the U.S.

Vericel's brand reputation in the past year appears to be generally positive, driven by product advancements, strategic initiatives, and positive analyst sentiment. The launch of MACI Arthro and the expansion of NexoBrid's indication have enhanced the company's product portfolio. Vericel has expanded its sales force and invested in surgeon training programs. The company reported strong revenue growth for MACI and its burn care segment. Several Wall Street analysts have issued "Buy" recommendations for VCEL, with TipRanks' AI Analyst rating VCEL as "Outperform." However, Seeking Alpha downgraded Vericel to a "Hold" rating in January 2026, citing inconsistent growth and fluctuating profitability.

Vericel Corp.'s ownership structure is predominantly characterized by institutional investment, holding approximately 75,008,654 shares. BlackRock Inc. holds approximately 14.97% to 15.86% of shares, Vanguard Group Inc. holds approximately 6.94% to 7.05% of shares, and State Street Corp holds approximately 4.82% to 5.55% of shares. Insider ownership is relatively small, around 1.06% to 10.15%.